Healthcare suppliers can simply order Myriad genetic testing for greater than 250 million sufferers inside the Epic . community
Partnership advances Myriad’s development plan to develop customer-centric, technology-enabled enterprise capabilities with greater than 600 EHR integrations this 12 months
SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, (NASDAQ: MYGN), the chief in genetic testing and precision drugs, right this moment introduced a partnership with Epic, the trade’s main healthcare software program firm, integrating your complete Myriad suite. of genetic testing with Epic’s increasing community of 600,000 physicians and greater than 250 million sufferers.
The combination creates a seamless, end-to-end workflow resolution for healthcare suppliers to request Myriad checks and overview outcomes instantly inside their day by day Epic platform with out extra steps or handbook ordering processes. Epic allows the safe trade of knowledge between healthcare organizations that look after sufferers.
With the power to overview related well being info, order checks, and obtain outcomes regionally at Epic, suppliers may have the essential genetic insights and associated info they should obtain higher well being outcomes and enhance affected person expertise. Sufferers will even be capable to simply entry Myriad take a look at outcomes and different well being info instantly via their EHR portal.
“Simplifying the genetic testing process by making it more intuitive and interoperable with electronic health records is an essential component of our mission to advance the health and well-being of all,” stated Paul J. Diaz, President and CEO of Myriad Genetics. “Our collaboration with Epic reflects our strategy of partnering with other healthcare industry leaders so that we can advance precision medicine together. Increasing access to genetic insights and integrating our tests into Epic’s vast network of healthcare systems is an important step forward to better serve patients and healthcare providers.”
As a part of its transformation and development plan, Myriad is specializing in new customer-centric and technology-enabled instruments to facilitate the genetic testing course of for sufferers and clinicians. With the current launch of Myriad’s Exact Oncology Options, suppliers can now submit a single request for numerous checks and get ends in a well timed method via a unified on-line portal. Now, by partnering with Epic, Myriad is increasing its efforts to assist clinicians and well being programs entry genetic testing quicker and extra conveniently inside the platform they use every single day.
“Genetic testing and precision medicine are saving lives,” stated Alan Hutchison, vp of inhabitants well being at Epic. “Through this relationship, we bring genetic insights to the point of care at scale, giving providers and patients the information they need to make informed and timely decisions.”
Myriad’s integration with Epic is anticipated to start later this 12 months.
About Numerous Genetics
Myriad Genetics is a number one genetic testing and precision drugs firm devoted to advancing the well being and well-being of all. Myriad develops and markets genetic checks that assist assess the chance of illness development or illness development and information remedy choices throughout medical specialties the place genetic insights can dramatically enhance affected person care and decrease well being care prices. Quick Firm named Myriad amongst Probably the most revolutionary corporations on the planet for 2022. For extra info, go to www.myriad.com.
Myriad, Brand Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, MyRisk MyRisk, MyRisk Hereditary Most cancers, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, PreciseI, FirstGeneluminated, Well being. . GeneSight and EndoPredict are emblems or registered emblems of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. all rights are save.
Protected Harbor Assertion
This press launch accommodates “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995, together with statements concerning the Firm’s merger of genetic testing with the Epic community of physicians and sufferers and the anticipated timing of the merger; The corporate’s development plan to develop customer-centric, technology-enabled enterprise capabilities with greater than 600 EHR integrations this 12 months; Anticipated advantages from the mixing, together with that the mixing will create a complete workflow resolution for healthcare suppliers to request numerous checks and overview outcomes instantly with their day by day Epic workflows, offering suppliers with vital genetic insights and related info they should obtain wholesome outcomes Higher and improved affected person expertise, permitting sufferers to simply entry their Myriad take a look at outcomes instantly from their EHR portal; and the corporate’s strategic imperatives underneath the title “About Myriad Genetics”. These “forward-looking statements” are administration’s present expectations of future occasions and are topic to quite a lot of dangers and uncertainties that might trigger precise outcomes to vary materially and adversely from these proven within the forward-looking statements. These dangers embody, however aren’t restricted to: the uncertainties related to COVID-19, together with its potential results on the Firm’s operations, the demand for its services, and the Firm’s potential to function its enterprise effectively and flexibly; The chance that gross sales and revenue margins will lower for the corporate’s present molecular diagnostics checks or that the corporate could not be capable to run its enterprise on a worthwhile foundation; Dangers associated to the corporate’s potential to generate ample income from its present product portfolio or in launching and advertising and marketing new checks; Dangers associated to adjustments in state or personal insurers’ protection and reimbursement ranges for the Firm’s checks or the Firm’s potential to acquire compensation for its new checks at ranges just like its present checks; dangers associated to elevated competitors and the event of recent competitors checks and providers; the chance that the corporate will be unable to develop or obtain business success for added molecular diagnostic checks in a well timed method, or in any respect; The chance that the Firm won’t reach growing new markets for its molecular diagnostic checks, together with the Firm’s potential to efficiently generate income exterior the US; the chance that licenses for the know-how upon which the Firm’s molecular diagnostics checks are based mostly and any future checks could also be terminated or can’t be held on passable phrases; Dangers associated to delays or different issues associated to the operation and building of the Firm’s laboratory testing services; Dangers associated to public concern about genetic testing usually or firm testing specifically; dangers associated to regulatory or enforcement necessities in the US and overseas nations and adjustments within the construction of the well being care system or well being care fee programs; Dangers associated to the Firm’s potential to amass new licenses or institutional collaborations and to amass or develop new applied sciences or companies on passable phrases, if any; dangers associated to the Firm’s potential to efficiently combine and profit from any applied sciences or companies it licenses, acquires or develops; Dangers associated to the Firm’s expectations about potential market alternatives for the Firm’s present and future merchandise; the chance that the Firm or its licensors will be unable to guard it or that third events will violate the proprietary applied sciences underlying the Firm’s checks; danger of patent infringement claims or challenges to the validity of the corporate’s patents; Dangers associated to adjustments in mental property legal guidelines protecting the corporate’s molecular diagnostic checks, patents or enforcement, in the US and overseas nations; dangers associated to safety breaches, information loss and different disruptions, together with cyber assaults; the dangers of recent, altering, and aggressive applied sciences and laws in the US and internationally; the chance of the Firm’s lack of ability to adjust to its monetary working covenants underneath the Firm’s credit score or lending agreements; Dangers associated to materials weak point associated to common IT controls, together with their affect and the Firm’s remedial plan, and its potential to attain and keep efficient disclosure controls and procedures and inner management over monetary reporting; dangers associated to present and future litigation, together with skilled or product legal responsibility claims; and different elements mentioned underneath “Risk Factors” in Part 1A of the Firm’s Annual Report on Kind 10-Okay filed with the Securities and Alternate Fee on February 25, 2022, in addition to any updates to those danger elements supplied occasionally specified within the firm’s quarterly experiences on Kind 10-Q or present experiences on Kind 8-Okay. The reported variety of medical doctors and sufferers within the Epic community was supplied by Epic.